30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective

Emerging evidence from the numerous clinical trials involving cytokine-induced killer (CIK) cell therapy suggests that its optimization in combination with other contemporary cancer therapies in a complementary manner (rather than as competition) will be a key to combat cancer.

Saved in:
Bibliographic Details
Published inJournal of experimental & clinical cancer research Vol. 40; no. 1; p. 388
Main Authors Sharma, Amit, Schmidt-Wolf, Ingo G H
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 09.12.2021
BioMed Central
BMC
Subjects
Cancer
Cancer therapies
Care and treatment
Cell- and Tissue-Based Therapy - methods
Clinical trials
Cytokine-induced killer (CIK) cell therapy
Cytokine-Induced Killer Cells - metabolism
Cytokines
Cytotoxicity
Dendritic cells
Epigenetics
Graft versus host disease
Humans
Immunotherapies
Immunotherapy
Immunotherapy - methods
Monoclonal antibodies
Neoplasms - drug therapy
Time Factors
Tumors
Immunotherapies
Cytokine-induced killer (CIK) cell therapy
Online AccessGet full text

Cover

More Information
Summary:Emerging evidence from the numerous clinical trials involving cytokine-induced killer (CIK) cell therapy suggests that its optimization in combination with other contemporary cancer therapies in a complementary manner (rather than as competition) will be a key to combat cancer.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:1756-9966
0392-9078
1756-9966
DOI:10.1186/s13046-021-02184-2